Technology | 2016.05.08
US IPO Weekly Recap: Biotechs Get Pushback, But Gene Editing Still Soars - Seeking Alpha
| 24/7 Wall St. | US IPO Weekly Recap: Biotechs Get Pushback, But Gene Editing Still Soars Seeking Alpha Intellia is utilizing the same CRISPR/Cas9 technology as Editas Medicine ((NASDAQ: EDIT ); +89% return), but is in earlier preclinical stages. The two are also in a battle over key patents, which will most likely end in a sharing of the IP. Insiders took ... Gene editing firm Intellia raises $163M in largest biotech IPO of 2016 Intellia Therapeutics Enters the Market With a Bang Bullish Intellia Therapeutics raises $108M in top-range IPO |
For more information, please visit
http://news.google.com/news/url?sa=t&fd=[...]ekly-recap-biotechs-get-pushba
Follow us on
Instagram is adding automatic in-app text translation - The Verge views: 1528
Here’s a ‘Brand-New’ Massive Multilingual Dataset for Machine Translation views: 1524